EGFR and colorectal carcinoma: Of note, treatment of CRC cell lines with other inhibitors of the RAS-MAPK pathway at different levels (EGFR inhibition, ERK1/2 inhibition) did not lead to changes in RAD51 levels, suggesting that the mechanism is specific to MEKi (Figure S10D).